Qatar vs Syrian Arab Republic: Access to anti-retroviral drugs, female
Qatar
43.0%
in 2024
Syrian Arab Republic
41.0%
in 2024
Qatar rank
126th
Syrian Arab Republic rank
127th
Access to anti-retroviral drugs, female over time
- Qatar
- Syrian Arab Republic
How they compare
Qatar currently reports 43.0% against 41.0% in Syrian Arab Republic, a difference of 2.0%.
The two have swapped places 1 time across 17 shared years of data; in 2000 it was Syrian Arab Republic ahead.
Qatar ranks 126th and Syrian Arab Republic ranks 127th of 141 countries.
Across the 3 decades both report, Qatar averaged higher in 2 and Syrian Arab Republic in 1.
Head to head by decade
| Decade | Qatar | Syrian Arab Republic | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 3.1% | 3.1% | Syrian Arab Republic |
| 2010s | 85.2% | 34.2% | 51.0% | Qatar |
| 2020s | 53.0% | 41.4% | 11.6% | Qatar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Qatar or Syrian Arab Republic?
- Qatar, at 43.0% against 41.0% in Syrian Arab Republic as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Qatar and Syrian Arab Republic?
- 2.0%, with Qatar ahead.
- How many years of comparable data are there for Qatar and Syrian Arab Republic?
- 17 years are reported by both, from 2000 to 2024.
- How do Qatar and Syrian Arab Republic rank globally for access to anti-retroviral drugs, female?
- Qatar ranks 126th and Syrian Arab Republic ranks 127th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.